Please login to the form below

Not currently logged in
Email:
Password:

axitinib

This page shows the latest axitinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

The ATLAS study was testing whether VEGF inhibitor Inlyta (axitinib) given as an adjuvant treatment after surgery to remove the tumour could improve disease-free survival compared to placebo, but has

Latest news

More from news
Approximately 7 fully matching, plus 27 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Pfizer’ s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines.

  • Oncology drugs under AMNOG

    Pfizer’ s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics